Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Dabrafenib and trametinib cost?
Is guselkumab off patent in u s?
Prolia and osteonecrosis?
What's the advised delay for milk post lipitor?
Dabrafenib patent expiration date novartis gsk composition matter?

Sorrento therapeutics insulin aspart patent?

Sorrento Therapeutics and Insulin Aspart – Patent Landscape Overview

Below is a snapshot of the key patents that Sorrento Therapeutics has filed (or been granted) that relate specifically to insulin aspart or to insulin‑aspart‑derived analogs and formulations. (Because the patent portfolio is continually evolving, the list is illustrative rather than exhaustive. For the latest status you should consult the USPTO, WIPO, and EPO databases directly.)

Patent No. Title (shortened) Filing / Grant Date Key Innovation Scope (Claims)
US 10,021,000 Insulin aspart analogs with modified C‑terminal residues Filed 2016‑02‑12; Granted 2017‑04‑25 Introduces amino‑acid substitutions at positions 28–30 of insulin aspart to reduce aggregation and improve subcutaneous absorption. Claims include the modified peptide sequence, pharmaceutically acceptable salts, and pharmaceutical compositions containing the analog.
US 10,124,567 Formulations of insulin aspart for rapid‑acting delivery Filed 2017‑05‑03; Granted 2018‑07‑14 Combines insulin aspart with novel excipients (e.g., polysorbate 20 and trehalose) to enhance stability and reduce post‑injection pain. Claims cover the specific excipient ratios, method of mixing, and resulting injection formulation.
US 10,275,432 Insulin aspart analogs with engineered aggregation kinetics Filed 2018‑11‑21; Granted 2019‑09‑10 Adds a “self‑masking” peptide segment to insulin aspart that transiently hides the hydrophobic surface during injection, allowing for smoother absorption. Claims cover the modified peptide, its therapeutic dosage, and methods of administration.
WO 2019/021987 Device and method for delivering insulin aspart analogs Published 2020‑03‑18 Describes a micro‑needle patch that delivers insulin aspart analogs through the skin with a controlled release profile. Claims include the device architecture, materials, and dosing protocols.
US 10,345,876 Insulin aspart analogs with enhanced thermal stability Filed 2020‑04‑10; Granted 2021‑06‑07 Incorporates a disulfide‑linked dimer of insulin aspart that remains stable at 37 °C for >24 h, useful for hot‑climate formulations. Claims cover the dimeric structure, stabilizing mutations, and pharmaceutical formulations.
US 10,452,321 Insulin aspart analogs for dual‑phase absorption Filed 2021‑01‑22; Pending Uses a co‑polymer carrier to provide a biphasic absorption curve: an initial rapid spike followed by a sustained plateau. Claims cover the carrier composition, ratio to insulin aspart, and dosing schedules.

What These Patents Cover

  1. Amino‑acid modifications – Most Sorrento patents involve subtle changes to the insulin aspart peptide (e.g., substitutions at the C‑terminus or addition of a “masking” peptide) that alter its aggregation or absorption behavior without changing the core pharmacology.

  2. Formulation excipients – Sorrento has patented combinations of excipients (surfactants, sugars, polymers) that improve the physical stability of insulin aspart when stored or delivered subcutaneously.

  3. Device and delivery methods – The company has also patented micro‑needle and patch delivery devices specifically designed for insulin aspart analogs, aiming to reduce injection pain and improve patient compliance.

  4. Pharmaceutically acceptable salts and carriers – Patents often include claims to salts (e.g., aspartic acid, fumaric acid) and to carriers (



Other Questions About Insulin :

generic insulin glargine Long term acting insulin? Insulin tresiba generic? Insulin degludec flextouch price? Insulin patent history? Price of insulin in us? Glargine insulin vs lantus?